Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis
Christian U. Blank(The Netherlands Cancer Institute), Michael P. Brown(South Australia Pathology), Ivana Krajsová(Charles University), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Geke A.P. Hospers(University Medical Center Groningen), Jacob Schachter, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Axel Hauschild(University Hospital Schleswig-Holstein), Wilson H. Miller(Jewish General Hospital), Enrique Espinosa(Hospital Universitario La Paz), Martina Makrutzki(Roche (Switzerland)), Susan Robson(Roche (Switzerland)), Vladan Antic(Roche (Switzerland)), Paola Queirolo, James Larkin(Trinity College Dublin), Bart Neyns(Universitair Ziekenhuis Brussel), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Helen Gogas(National and Kapodistrian University of Athens), Claus Garbe(University of Tübingen)
Cited by 36
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k